Lukang Township

Researchers are evaluating the combination of Surovatamig AZD0486, a fully human bispecific monoclonal IgG4 antibody, plus rituximab versus standard immunochemotherapy regimens in adults with untreated follicular lymphoma FL. This global, randomized, open-label Phase III study aims to assess the efficacy, safety, and added benefit of this combination compared to investigator-chosen standard treatments. The study includes a safety run-in and a Phase III portion with three treatment arms. The study has two parts first, a Safety Run-in to determine the recommended Phase III dose RP3D of Surovatamig combined with rituximab second, a Phase III comparison of Surovatamig plus rituximab two dosing schedules against one of three standard chemoimmunotherapy regimens chosen by the investigator R-CVP, R-CHOP, or B-R, all followed by rituximab maintenance. Participants are assigned to one of these three arms to evaluate treatment effects. Participants will be monitored for up to 10 years, with assessments including adverse event tracking, dose adjustments, and efficacy measures such as response rates, progression-free survival, and overall survival. Evaluations involve physical exams, laboratory tests, and imaging to measure disease activity and safety. The study aims to gather long-term data on treatment impact and safety in this patient population.

Researchers are studying ziftomenib, an investigational drug targeting the menin pathway, in patients with acute myeloid leukemia AML who have specific genetic mutations NPM1-m or KMT2A-r and have not yet received treatment. The study includes two separate phase 3, randomized, double-blind, placebo-controlled trials assessing ziftomenib combined with standard therapies. The goal is to evaluate the benefits and risks of adding ziftomenib to current standard treatments for AML. One study, called the Nonintensive Therapy Study, enrolls older patients or those with serious medical conditions to receive venetoclax and azacitidine standard care plus either ziftomenib or placebo. The second study, the Intensive Therapy Study, involves medically fit patients treated with cytarabine and daunorubicin known as 73 plus ziftomenib or placebo during induction, followed by cytarabine plus ziftomenib or placebo in consolidation, and a maintenance phase where patients receive ziftomenib or placebo alone. Patients are randomly assigned to these groups without knowing which treatment they receive. Participants will undergo regular assessments to monitor overall survival, event-free survival, remission rates, and measurable residual disease in bone marrow up to 36 months after enrollment. Safety is evaluated through adverse event reporting and drug concentration measurements. Patient-reported outcomes related to health are also collected. The study involves oral and intravenous drug administration with visits scheduled according to treatment phases. Participation lasts up to 36 months, including treatment and follow-up periods.